Lipum has been granted funding from Swelife
Lipum (publ) announce today that the project “Identifying proteomic biomarkers to predict the course of early RA” has been granted 2,8 MSEK from Swelife. The project is a collaboration between Lipum, Karolinska institutet, Stockholm and Linköping University.
Rheumatoid arthritis (RA) is a debilitating chronic inflammatory disease that significantly impacts patients’ quality of life and affect up to 1% of the world’s population or 18 million people. Lipum has discovered the Bile Salt-Stimulated Lipase (BSSL) as a novel target for treatment of RA and developed a monoclonal humanized antibody (SOL-116) directed against BSSL as a promising candidate drug (currently in the end of a phase 1 clinical study).
In the project, we will define a panel of carefully selected protein biomarkers assembled to accurately predict arthritis development and the disease course in patients with increased risk of RA and patients with recent-onset disease. Particularly, we will search for biomarkers associated with BSSL serum levels that can predict response to Lipum’s lead candidate drug SOL-116 and lay the foundation for a companion diagnostic test which in the end will increase the chance of SOL-116 to reach the market.
Swelife – For a competitive life science ecosystem in Sweden – is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme’s partners. They support collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.
We are very grateful for the support we have received from Swelife. This funding enables a very important collaboration between Lipum, Karolinska Institutet and Linköping university where it will give us the opportunity to identify proteomic biomarkers to predict the course of early RA”, says Ola Sandborgh, CEO Lipum.
Contacts
Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: www.lipum.se
About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company’s share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.
Attachments
Lipum has been granted funding from Swelife